Agathic Acid

Agathic Acid

SCHEMBL21914839

C=C1CCC2C(C)(C(=O)O)CCCC2(C)C1CC/C(C)=C/C(=O)O

nearest known ligand 0.64

Full drug profile on Sugi Atlas →

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
TAS2R31 P59538 1/20 0.64
POLB P06746 1/20 0.62
MAPT P10636 1/20 0.62
PTPN1 P18031 7/20 0.61
CYP2C9 P11712 1/20 0.46
CYP2C19 P33261 1/20 0.46
LMNA P02545 1/20 0.44
CYP3A4 P08684 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
MMP2 P08253 1/20 0.44
PTPN2 P17706 1/20 0.44
PNLIP P16233 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Agathic Acid SCHEMBL30436331 1.00 TAS2R31 (0.64) TAS2R31POLBMAPTPTPN1CYP2C9
Agathic Acid SCHEMBL29358171 1.00 TAS2R31 (0.64) TAS2R31POLBMAPTPTPN1CYP2C9
SCHEMBL30436964 0.90 POLB (0.58) TAS2R31POLBMAPTPTPN1CYP2C9
Isocupressic Acid SCHEMBL13532265 0.89 POLB (0.66) TAS2R31POLBMAPTPTPN1CYP2C9
Isocupressic Acid SCHEMBL19139984 0.89 POLB (0.66) TAS2R31POLBMAPTPTPN1CYP2C9
Copalic Acid SCHEMBL25221800 0.89 TAS2R31 (0.66) TAS2R31POLBMAPTPTPN1LMNA
Copalic Acid SCHEMBL29481956 0.89 TAS2R31 (0.66) TAS2R31POLBMAPTPTPN1LMNA
Copalic Acid SCHEMBL34460866 0.89 TAS2R31 (0.66) TAS2R31POLBMAPTPTPN1LMNA
SCHEMBL15214261 0.88 POLB (0.64) TAS2R31POLBMAPTPTPN1CYP2C9
SCHEMBL21914841 0.88 TAS2R31 (0.63) TAS2R31POLBMAPTPTPN1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12624263-B2 Dimensionally stable, wipe-on, modified-polyether-polyurethane-based adhesive compound HENKEL AG & CO. KGAA (DE) 2026-05-12 US disclosed
US-12577446-B2 Dimensionally stable, wipe-on, semi-crystalline-polyester-based adhesive compound HENKEL AG & CO. KGAA (DE) 2026-03-17 US disclosed
US-20250064716-A1 COSMETIC COMPOSITION COMPRISING A NATURAL RESIN L'OREAL (FR) 2025-02-27 US disclosed
EP-4452200-A1 COSMETIC COMPOSITION COMPRISING A NATURAL RESIN L'OREAL (FR) 2024-10-30 EP disclosed
WO-2023118430-A1 COSMETIC COMPOSITION COMPRISING A NATURAL RESIN L'OREAL (FR) 2023-06-29 WO disclosed
EP-4077449-A1 DIMENSIONALLY STABLE, WIPE-ON, SEMI-CRYSTALLINE POLYESTER-BASED ADHESIVE COMPOUND Henkel AG & Co. KGaA (DE) 2022-10-26 EP disclosed
EP-4077448-A1 DIMENSIONALLY STABLE, WIPE-ON, MODIFIED POLYETHER-POLYURETHANE-BASED ADHESIVE COMPOUND Henkel AG & Co. KGaA (DE) 2022-10-26 EP disclosed
US-20220306918-A1 DIMENSIONALLY STABLE, WIPE-ON, MODIFIED-POLYETHER-POLYURETHANE-BASED ADHESIVE COMPOUND HENKEL AG & CO. KGAA (DE) 2022-09-29 US disclosed
US-20220306919-A1 DIMENSIONALLY STABLE, WIPE-ON, SEMI-CRYSTALLINE-POLYESTER-BASED ADHESIVE COMPOUND HENKEL AG & CO. KGAA (DE) 2022-09-29 US disclosed
CN-114846048-A Dimensionally stable, spreadable adhesive mass based on modified polyether polyurethanes 汉高股份有限及两合公司 2022-08-02 CN disclosed
CN-114829439-A Dimensionally stable, spreadable adhesive mass based on semicrystalline polyesters 汉高股份有限及两合公司 2022-07-29 CN disclosed
US-11311591-B2 Use of copaifera oleoresin in pathologies of the prostate PIERRE FABRE MEDICAMENT (FR) 2022-04-26 US disclosed
US-10925915-B2 Use of a Copaifera extract to combat alopecia and seborrhea PIERRE FABRE DERMO-COSMETIQUE (FR) 2021-02-23 US disclosed
US-20200093879-A1 USE OF COPAIFERA OLEORESIN IN PATHOLOGIES OF THE PROSTATE PIERRE FABRE MEDICAMENT (FR) 2020-03-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11311591-B2 Use of copaifera oleoresin in pathologies of the prostate ACP3, BPHL, CYP17A1 TAS2R31 4363/4885POLB 2539/4885MAPT 1210/4885
US-10925915-B2 Use of a Copaifera extract to combat alopecia and seborrhea CUTA, CYP17A1, CYP51A1 TAS2R31 2510/4885POLB 1736/4885MAPT 1566/4885
US-12577446-B2 Dimensionally stable, wipe-on, semi-crystalline-polyester-based adhesive compound MACF1, WAPL, ICAM1 TAS2R31 3061/4885POLB 2470/4885MAPT 58/4885
US-20200093879-A1 USE OF COPAIFERA OLEORESIN IN PATHOLOGIES OF THE PROSTATE ACP3, BPHL, CYP17A1 TAS2R31 4363/4885POLB 2539/4885MAPT 1210/4885
US-12624263-B2 Dimensionally stable, wipe-on, modified-polyether-polyurethane-based adhesive compound MACF1, ICAM1, ILK TAS2R31 2333/4885POLB 3738/4885MAPT 51/4885
US-20250064716-A1 COSMETIC COMPOSITION COMPRISING A NATURAL RESIN KRT18, CUTA, RARA TAS2R31 850/4885POLB 1242/4885MAPT 167/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.